5-Amino-1MQ: Benefits, Dosage & FDA Status
5-Amino-1-Methylquinolinium
A small-molecule NNMT inhibitor that has produced fat loss and improved muscle stem-cell function in obese rodents. No human RCTs yet.
FDA Status
Not FDA-approved — small-molecule research compound (NNMT inhibitor)
Typical Dose
50–150 mg orally daily (research-only)
Evidence Grade
C+Preclinical evidence + anecdotal clinical use
Half-Life
~6 hours
Routes of Administration
oral
First Synthesized
2018
Clinics Indexed
31 providers have offered 5-Amino-1MQ in our tracked directory.
Mechanism of Action
Selective inhibitor of nicotinamide N-methyltransferase (NNMT); raises NAD+/SAM ratio and shifts adipocyte energy expenditure.
Key Reported Benefits
- ✓NNMT inhibition
- ✓Fat-mass reduction (preclinical)
- ✓Muscle stem-cell support
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade C+ indicates preclinical evidence + anecdotal clinical use.
Reported Side Effects
- •Mild GI upset
- •Headache
Contraindications
- ⚠Pregnancy
Regulatory & Safety Context
FDA status: Not FDA-approved — small-molecule research compound (NNMT inhibitor)
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
See state-by-state legality: US peptide legality by state →
References
Selected primary literature on 5-Amino-1MQ. Full PubMed records linked. Additional citations are available on request.
Last reviewed: 2026-04-30
Related Peptides
AOD-9604
C+A modified fragment of human growth hormone (hGH 176-191) that stimulates fat breakdown without the growth-promoting or diabetogenic effects of full HGH.
Tesamorelin
AAn FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.
Epitalon
C+A synthetic tetrapeptide that reportedly upregulates telomerase activity. Russian longevity studies suggest mortality reductions but Western RCTs are absent.
MOTS-c
BA 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.
SS-31
B+A cell-permeable tetrapeptide that targets cardiolipin in the inner mitochondrial membrane. Investigated for primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration.
Pinealon
CA short tripeptide developed in Russia for cognitive aging and oxidative stress. Limited Western clinical evidence.